Journal September 26, 2026 6 min read

What markers track neuroinflammation?

Neuroinflammation is tracked by a range of cellular, molecular, and imaging markers. This page surveys the evidence for key markers and the pathways they reflect, from astrocytic and microglial activation to inflammasome

peptides-pro Editorial

Neuroinflammation is a complex response of the central nervous system involving activation of glial cells, release of inflammatory mediators, and disruption of the blood-brain barrier. It is tracked by markers that reflect these processes, including astrocytic and microglial activation, inflammasome assembly, and metabolic shifts. The formal name for this set of indicators is neuroinflammatory biomarkers; they include proteins such as glial fibrillary acidic protein (GFAP), cytokines like interleukin-1 beta (IL-1β), and imaging signals from positron emission tomography (PET) ligands. No single marker captures the full picture; instead, a panel is often used to assess different aspects of the inflammatory cascade.

The work centres on the NLRP3 inflammasome pathway, which is a key mediator of neuroinflammation in many neurological conditions. This pathway involves the activation of nucleotide-binding oligomerization domain, leucine-rich repeat, and pyrin domain-containing protein 3 (NLRP3), leading to caspase-1 activation and the release of pro-inflammatory cytokines IL-1β and IL-18. Markers of this pathway include NLRP3 protein levels, caspase-1 activity, and cytokine concentrations in cerebrospinal fluid or brain tissue.

Research Studies

Magnesium sulphate and NMDA receptor blockade in neonatal asphyxia

In term neonates with birth asphyxia, intravenous magnesium sulphate is under investigation for its neuroprotective effects. Magnesium sulphate blocks NMDA receptors, limiting cellular calcium influx and neuroinflammation. A randomized controlled trial is evaluating whether adjuvant intravenous magnesium sulphate (250 mg/kg within 6 hours of birth) reduces the duration of hospital stay and improves short-term clinical outcomes in this population [1]. The study focuses on clinical outcomes rather than specific neuroinflammatory markers, but the mechanism suggests that markers of excitotoxicity and inflammation could be relevant.

Tauroursodeoxycholate and liver-targeted therapy in diabetic macular edema

Diabetic macular edema, a complication of diabetic retinopathy, involves neuroinflammation and vascular dysfunction. Tauroursodeoxycholate (TUDCA), a bile acid, is being explored as a nutraceutical supplement that may address systemic inflammation linked to hepatic metabolic dysfunctions. A clinical trial is investigating integrative liver-targeted therapy using TUDCA or traditional Chinese medicine for diabetic macular edema [2]. The premise is that liver metabolism influences neuroinflammation, but specific markers of neuroinflammation in this context are not detailed in the available evidence.

Astrocytic failure and NLRP3 inflammasome in Parkinson's disease

In Parkinson's disease, astrocyte dysfunction is increasingly recognized as a driver of pathogenesis. Pathological α-synuclein triggers astrocytic failure, including impaired proteostasis, glymphatic system collapse due to aquaporin-4 (AQP4) depolarization, and chronic neuroinflammation driven by microglial crosstalk and NLRP3 inflammasome activation [3]. Markers of these processes include α-synuclein aggregates, AQP4 localization, and NLRP3 inflammasome components. This review synthesizes evidence from human and animal studies, highlighting the multicellular nature of neuroinflammation.

AMPK activation and NLRP3 inflammasome suppression in traumatic brain injury

In a weight-drop model of traumatic brain injury in Sprague-Dawley rats, AMPK activation was associated with suppression of NLRP3 inflammasome-mediated neuroinflammation. AMPK activators such as metformin, quercetin, resveratrol, cinnamaldehyde, and berberine were investigated for their neuroprotective effects [4]. Markers included NLRP3 inflammasome components and downstream cytokines. This study is animal-only, so findings may not directly translate to humans.

Natural medicines and mechanistic insights in Alzheimer's disease

A bibliometric analysis and narrative review mapped research trends in natural medicines for Alzheimer's disease, examining mechanistic evidence from experimental studies [5]. The review covers various pathways, including neuroinflammation, but does not focus on specific markers. It provides a landscape view of how natural compounds are studied in the context of Alzheimer's disease, where neuroinflammation is a key feature.

Oxiracetam and cognitive impairment in neurological disorders

Oxiracetam, a nootropic, has been evaluated for cognitive dysfunction in conditions such as aging, neurodegenerative diseases, stroke, and traumatic brain injury. A narrative review synthesized preclinical and clinical literature on its mechanistic basis, including effects on cholinergic and other systems [7]. While neuroinflammation is not the primary focus, cognitive impairment often involves inflammatory components. The review discusses clinical efficacy and safety, but specific neuroinflammatory markers are not highlighted.

NMNAT-1 and NAD+ homeostasis in neuroprotection

Nicotinamide mononucleotide adenylyltransferase 1 (NMNAT-1) catalyzes the final step in NAD+ biosynthesis and is the major nuclear isoform. NAD+ decline is implicated in brain aging and neurodegenerative disorders. Direct human genetic evidence establishes NMNAT-1 as a causal gene in inherited retinal degeneration, and its role in neuroprotection may involve modulation of inflammation [8]. Markers of NAD+ homeostasis, such as NAD+ levels and NMNAT-1 expression, could serve as indirect indicators of neuroinflammatory status, though the link is not fully defined.

Bilirubin and microglial lipophagy via AMPK-mTOR

In hyperbilirubinemia, unconjugated bilirubin induces neuroinflammation, contributing to bilirubin encephalopathy. A study investigated how bilirubin impacts microglial lipophagy via the AMPK-mTOR signaling pathway [10]. This research is REFERENCE ONLY; it reports that bilirubin disrupts lipophagy, potentially exacerbating neuroinflammation. Markers include components of the AMPK-mTOR pathway and lipophagy-related proteins. The study is likely preclinical, and the findings are specific to hyperbilirubinemia models.

Pterostilbene in hyperhomocysteinemia-induced cognitive impairment

Pterostilbene, a natural stilbene, was studied for its neuroprotective mechanisms in hyperhomocysteinemia-induced cognitive impairment using in silico, proteomics, and experimental validation [11]. This REFERENCE ONLY item reports that pterostilbene modulates antioxidant and anti-inflammatory pathways. Markers may include oxidative stress indicators and inflammatory cytokines, but the evidence is not detailed here. The study combines computational and experimental approaches, likely in animal models.

TRIM28 SUMOylation and astrocytic IRF3 in ischemic injury

In ischemic cerebral injury, TRIM28 (an E3 SUMOylase) SUMOylates IRF3 in astrocytes, driving neutrophil infiltration. This REFERENCE ONLY study identified a mechanism linking astrocytic TRIM28 to immune cell recruitment [12]. Markers include TRIM28 expression, IRF3 SUMOylation, and neutrophil infiltration. The research is likely in animal models of stroke, and the findings highlight a specific pathway in neuroinflammation.

If you are reading this for personal health reasons

The materials and compounds discussed here are sold for laboratory research purposes only. We do not provide dosing, medical guidance, or recommendations for personal use. If you are considering any compound for yourself, you must consult a licensed clinician.